Massachusetts |
001-38787 |
83-1895370 |
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class
| Trading Symbol(s) | Name of each exchange on which registered | ||
Common Stock, no par value |
CYCN | The Nasdaq Stock Market LLC |
Item 3.02 |
Unregistered Sales of Equity Securities.
|
Item 5.03 |
Amendment to Articles of Incorporation or Bylaws.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit No. |
Description |
Articles of Amendment to the Restated Articles of Organization of the Company, as amended.
| |
104
|
Cover Page Interactive Data File
|
Cyclerion Therapeutics, Inc.
| |||
Dated: May 25, 2023
|
By:
|
/s/ Anjeza Gjino
| |
Name:
|
Anjeza Gjino
| ||
Title:
|
Chief Financial Officer
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Cyclerion Therapeutics Inc. published this content on 25 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2023 20:58:47 UTC.